Loading clinical trials...

Proactive Outreach With FIT | Clinical Trials | Clareo Health

ENROLLING_BY_INVITATIONNA

Proactive Outreach With FIT

A Randomized, Multi-site Trial to Boost Colorectal Cancer Screening Rates Through Proactive Outreach and Navigation in Federally Qualified Health Centers in Brooklyn

NCT06269744•NYU Langone Health

View on ClinicalTrials.gov

Summary

The purpose of the study is to boost colorectal cancer (CRC) screening rates in an underserved population in Brooklyn through organized, proactive outreach of mailed Fecal Immunochemical Tests (FIT), utilizing evidence-based interventions tailored to the needs of the population.

Eligibility

Age

45 - 75 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Patients
•Men and women aged 45-75
•Receiving medical care at NYULH Flatbush FHC and CHN Crown Heights, East New York, East New York Health Hub, Williamsburg clinic sites.
•Due or overdue for CRC screening.
•Medical visit of any type at clinic in past year.
•Providers
•Physicians or primary care givers at Flatbush FHC or CHN Crown Heights, East New York, East New York Health Hub, Williamsburg clinic sites (CHN employees)
•Provide care to CRC screen-eligible patients

Exclusion Criteria

•Age younger than 45 years old or greater than 75 years old
•Up-to-date with colorectal cancer screening:
•History of colorectal cancer, inflammatory bowel disease, colorectal polyps, or total colectomy
•In hospice care
•Patients 66 years or older living long-term in an institution or with advanced illness
•No address or phone number on file
•Providers
•No longer employed at an included clinic site

Locations (2)

NYU Langone Health

Brooklyn, New York, United States

Community Health Care Network of New York

Brooklyn, New York, United States

Key Dates

Start Date

March 13, 2024

Primary Completion Date

December 15, 2025

Completion Date

April 30, 2026

Last Updated

December 2, 2025

Enrollment

3,000

ESTIMATED participants

Conditions

Colorectal Cancer

Interventions

Proactive Screening Outreach

BEHAVIORAL

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Proactive Outreach With FIT

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors